Pfizer announced on Tuesday, November 1, positive results for its vaccine – under development – against the respiratory syncytial virus (RSV) causing the disease of bronchiolitis.
Soon a vaccine on the market to fight against bronchiolitis? Pfizer is not that far off. The American laboratory shared, Tuesday, November 1, positive results for its respiratory syncytial virus (RSV) vaccine)responsible for bronchiolitis. The latter must, however, be given to the mother during pregnancy.
This announcement comes as the bronchiolitis epidemic undermines French hospitals at the start of November.
An encouraging test
The vaccine showed itself 82% effective in preventing serious cases in a baby’s first three monthsand about 69% within six monthsaccording to the results of this phase 3 test, reports Le Figaro.
However, the laboratory did not conclude that vaccine reduced non-severe cases ‘statistically significantly’even if the tests show a certain clinical effectiveness, indicates Le Parisien.
The results have not yet been reviewed by independent scientists. According to 20 minutes, the American giant plans to request “authorization for the vaccine in pregnant women by the end of the year in the United States then in other countries“.
Waiting for the European Commission
Before it hits the market, Pfizer’s vaccine must first receive the green light from the European Commission. Other laboratories are also working on the development of vaccines against RSV. This is particularly the case British GSK and of the Americans Moderna and Johnson & Johnson.
Last September, Sanofi and Astrazeneca already had received a favorable opinion of the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency for its vaccine named Beyfortus.